T 1992/21 (Natalizumab and PML/BIOGEN) of 07.12.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T199221.20221207
- Date of decision
- 7 December 2022
- Case number
- T 1992/21
- Online on
- 13 February 2023
- Petition for review of
- -
- Application number
- 13175987.0
- IPC class
- A61K 45/06A61K 49/00A61K 39/00C07K 16/28A61K 38/03G01N 33/53A61K 39/395G01N 33/68A61K 38/21
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Methods of treating inflammatory and autoimmune diseases with natalizumab
- Applicant name
- Biogen MA Inc.
- Opponent name
- Polpharma Biologics S.A.
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(6)European Patent Convention Art 56
- Keywords
- Amendment to case - reasons for submitting amendment in appeal proceedings (no)
Inventive step - (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.